Compare Linde PLC (LIN) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Linde PLC vs Recursion Pharmaceuticals Inc — how do they compare? Linde PLC trades at $483.73 (market cap $222.05B), while Recursion Pharmaceuticals Inc trades at $4.36 (market cap $2.14B). The key difference: Linde PLC is far larger — about 103.8× Recursion Pharmaceuticals Inc's market cap, and Linde PLC pays a 1.33% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Linde PLC for 88 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| LIN | RXRX | |
|---|---|---|
Market Cap | $222.05B | $2.14B |
Volume | 2,116,440 | 30,789,535 |
Sector | Basic Materials | Health |
52-Week High | $546.64 | $6.79 |
52-Week Low | $389.38 | $2.84 |
Typical Hold Time | 88 Days | 23 Days |
Enterprise Value | $245.17B | $1.66B |
Dividend Yield | 1.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Linde (LIN) trades at $481.70, down 0.47% on the day, with strong technical momentum showing a bullish moving average signal. The company demonstrates robust fundamentals with consistent earnings beats, including Q2 2026 EPS of $4.50 beating estimates of $4.49, and maintains healthy profitability with a 20.43% net income margin. Analyst sentiment remains overwhelmingly positive with 89.66% buy ratings and a $557.10 consensus price target representing 15.6% upside potential from current levels.
The outlook remains favorable given Linde's leadership in industrial gases and exposure to AI chip manufacturing growth, though valuation at 31.08 P/E requires continued execution. Key risks include margin pressure from higher capital expenditures and competitive dynamics in the electronics sector. The stock's technical setup suggests support near $479 with resistance at $485, providing clear levels for near-term price action.
RXRX trades at $4.36, up 2.11% today, with technical indicators showing a bullish trend. The company reported Q3 2026 revenue of $54 million but continues to post significant losses with a -961.97% net income margin. Recent strategic partnerships with Tempus and Roche are expanding its AI-driven drug pipeline, though the stock faces high short interest and substantial cash burn from operations.
The outlook remains speculative given persistent losses and high valuation multiples (P/S 37.14), but analyst consensus leans positive with 40% buy ratings. Key risks include execution on drug development timelines and dependence on financing activities to fund operations. Upside potential hinges on successful clinical milestones from its expanding pipeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Linde PLC
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.
Read more on LIN →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
